WEDNESDAY, Jan. 15, 2020 -- From 2011 to 2017, there was an increase in gross annual expenditures on Multiple Sclerosis (MS) disease-modifying therapies (DMTs), with increased spending mainly driven by increases in per-prescription costs, according... (Source: Drugs.com - Pharma News)


Read full article on medworm.com


Powered by Preisvergleich